• Oligo (dT) 25 Beads: Reliable mRNA Isolation for Cell Assays

  2026-07-16

  This article addresses real-world challenges in mRNA purification for cell viability and cytotoxicity assays, demonstrating how Oligo (dT) 25 Beads (SKU K1306) deliver robust, reproducible results. Scenario-driven insights and data-grounded recommendations empower biomedical researchers to achieve high-quality eukaryotic mRNA isolation, supporting downstream applications including RT-PCR and transcriptomic profiling.

• CBX2–RACK1–HDAC1 Complex Suppresses Tumor Immunogenicity

  2026-07-16

  This study uncovers a noncanonical mechanism by which CBX2, a polycomb group protein, suppresses interferon signaling and reduces tumor immunogenicity through formation of a corepressor complex with RACK1 and HDAC1. These findings clarify how CBX2 modulates the tumor microenvironment and suggest potential new targets and biomarkers for improving cancer immunotherapy.

• PD0325901: MEK Inhibitor Workflows for Cancer and Stem Cell

  2026-07-15

  PD0325901 empowers researchers to dissect RAS/RAF/MEK/ERK signaling with high precision, enabling robust models of cell cycle arrest and apoptosis induction. Discover advanced workflows, troubleshooting strategies, and data-driven protocol tips that maximize translational value in both cancer and stem cell studies.

• DR5 Agonist Antibodies Trigger Unexpected PD-L1 Immune Evasi

  2026-07-15

  The referenced study reveals that DR5 agonist antibodies, developed to induce apoptosis in solid tumors, unexpectedly stabilize PD-L1 on tumor cells, promoting immune evasion. This mechanistic insight challenges prior assumptions about the efficacy of extrinsic apoptosis-inducing therapies and informs combinatorial strategies for solid tumor immunotherapy.

• ICG001: Precision Wnt/β-Catenin Pathway Inhibitor in Transla

  2026-07-14

  ICG001 enables targeted dissection of CBP/β-catenin signaling, empowering researchers to model cancer, fibrosis, and stem cell fate with greater specificity. This article details best-practice workflows, troubleshooting, and the latest protocol insights to maximize the impact of ICG001 in applied biomedical research.

• Ruxolitinib (INCB018424): Protocols and Pitfalls in JAK-STAT

  2026-07-14

  Ruxolitinib (INCB018424) empowers high-fidelity JAK-STAT pathway inhibition, enabling precision in myeloproliferative disorder and immune modulation studies. This guide demystifies advanced workflows, protocol parameters, and troubleshooting strategies for leveraging Ruxolitinib in translational and preclinical research.

• ZDHHC4-Mediated Palmitoylation Regulates TRPV1 Pain Signalin

  2026-07-13

  This study uncovers how the palmitoyl acyltransferase ZDHHC4 modifies TRPV1 via S-palmitoylation, leading to its lysosomal degradation and attenuation of pain signaling. By elucidating the molecular interplay between palmitoylation and the relief phase of inflammatory pain, the findings provide a mechanistic foundation for targeting TRPV1 regulation in analgesic development.

• Aprotinin (BPTI) in Cardiovascular Research: Applied Workflo

  2026-07-13

  Leverage Aprotinin (Bovine Pancreatic Trypsin Inhibitor, BPTI) from APExBIO for reproducible inhibition of serine proteases in cardiovascular and inflammation research. This guide delivers actionable workflows, troubleshooting tips, and protocol insights to maximize experimental success in perioperative blood loss reduction and red blood cell membrane studies.

• Oligo (dT) 25 Beads: Precision mRNA Isolation with Superpara

  2026-07-12

  Oligo (dT) 25 Beads enable rapid, high-purity eukaryotic mRNA isolation using superparamagnetic technology, streamlining workflows from total RNA extraction to next-generation sequencing. Explore advanced use-cases, optimization strategies, and troubleshooting tips to achieve maximal yield and purity, even in challenging experimental scenarios.

• Deuterated Tetrazole CYP51 Inhibitors: New Advances in Antif

  2026-07-10

  The referenced study introduces a deuterated tetrazole CYP51 inhibitor (V23) with broad-spectrum and in vivo antifungal efficacy, addressing limitations of earlier azole drugs such as metabolic instability and human CYP inhibition. This research advances the development of safer, more effective agents for invasive fungal infections, particularly those involving drug-resistant strains.

• Lipid-Like Nanoassemblies Enable Potent mRNA Delivery for SA

  2026-07-09

  This study introduces a novel class of lipid-like nanoassemblies (LLNs) that dramatically enhance the stability and in vivo translation efficiency of synthetic mRNA, enabling secretion of high-affinity truncated ACE2 variants as SARS-CoV-2 decoys. These findings provide a robust foundation for next-generation mRNA-based protein therapies and antiviral strategies.

• Deracoxib–Doxorubicin Combination Protects Canine Mammary Ce

  2026-07-09

  This study demonstrates that Deracoxib, a selective COX-2 inhibitor, can mitigate doxorubicin-induced cytotoxicity, apoptosis, and nitric oxide overproduction in normal canine mammary epithelial cells. These findings highlight a mechanistic basis for using Deracoxib to reduce chemotherapy-associated toxicity in veterinary oncology research.

• KR-12 Human Antimicrobial Peptide: Applied Workflows & Insig

  2026-07-08

  KR-12, the minimal LL-37 fragment, delivers potent, selective antimicrobial and anti-biofilm action with excellent mammalian cell safety, making it an agile tool for infection and inflammation research. This guide translates recent reference findings and workflow innovations into actionable protocols, troubleshooting strategies, and advanced use-cases for KR-12 (human) TFA.

• H-Aggregated NIR-II Fluorophores for Enhanced Tumor PTT

  2026-07-08

  Yu et al. (2023) present a lipid nanosystem that achieves direct transfer of H-aggregated NIR-II fluorophores to tumor cell membranes, enabling improved photothermal therapy (PTT) and real-time imaging. This approach overcomes key challenges in organic fluorophore stability and photothermal conversion, paving the way for more precise and effective cancer theranostics.

• Bacitracin (B1670): Technical Guidance for Antibacterial Res

  2026-07-07

  Bacitracin (B1670) is a peptide antibiotic formulated for laboratory research targeting bacterial cell wall and peptidoglycan synthesis disruption in both gram-positive and gram-negative bacteria. It is strictly for controlled research workflows and not for diagnostic or medical use. Reliable results depend on rigorous protocol adherence and quality-controlled materials.

15527 records 4/1036 page Previous Next 12345 下5页 Last page